Vanguard Group’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Vanguard Group’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-9,226,008	Closed	-$497M	–	4123
2017 Q4	$497M	Buy	9,226,008 +265,987	+3%	+$14.6M	0.02%	757
2017 Q3	$511M	Buy	8,960,021 +163,614	+2%	+$9.58M	0.02%	713
2017 Q2	$529M	Buy	8,796,407 +79,045	+0.9%	+$4.5M	0.03%	679
2017 Q1	$475M	Buy	+8,717,362	New	+$429M	0.02%	719

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Vanguard Group's BIVV Position: Q1 2018 in Review

Vanguard Group sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 9,226,008 shares — an estimated $497M sold.

Vanguard Group first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $529M in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Vanguard Group reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Vanguard Group sold 9,226,008 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $497M.
Vanguard Group first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Vanguard Group's Bioverativ Inc. Common Stock position peaked at $529M in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Vanguard Group's 13F filing for Q1 2018, filed 15 May 2018.